The management of dermatomyositis: current treatment options

Bibliography

• ISAACS D FD: Seven alternatives to evidence based medicine. iBr. Med. J. i (1999) 319:1618.
   PubMedGoogle Scholar
• EUWER RL, SONTHEIMER RD: Dermatomyositis (Chapter 2). In: Cutaneous Manifestations of Rheumatic iDiseases (1st edit). i Sontheimer RD, Provost TT (Eds), Williams & Wilkins, Baltimore, USA (2003).
   Google Scholar
• Cutaneous manifestations of rheumatic idiseases (2'd edit). i Sontheimer RD, Provost TT (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2003).
   Google Scholar
• Dermatological signs of Paternal disease i(Jd edit). Callen i JP, Jorrizo JL (Eds), WB Saunders, Philadelphia, USA (2003).
   Google Scholar
• Skin Signs of Systemic Disease (.7d edit). Braverman IM (Ed.), WB Saunders, Philadelphia, USA (1998).
   Google Scholar
• Dermatology (Pt edit). i Bolognia JL, Jorrizo JL, Rapini RP (Eds), Mosby, London, UK (2003).
   Google Scholar
• SONTHEIMER RD, COSTNER M: Dermatomyositis (Chapter 172). In: Dermatology in General Medicine Oh edit). Freedberg IM, Eisen AZ, Wolff K iet al. i(Eds), McGraw-Hill, New York, USA (2002).
   Google Scholar
• •A recent comprehensive treatment in a general dermatology textbook of all clinical issues relating to the cutaneous manifestations of dermatomyositis containing colour photographs of representative dermatomyositis skin changes.
   Google Scholar
• COSTNER M, PROVOST Ti SONTHEIMER RD: Lupus erythematosus. In: iCutaneous Manifestations of Rheumatic Diseases (2'd edn). i Lippincott Williams & Wilkins, Philadelphia, USA (2003).
   Google Scholar
• •A chapter from a recent dermatology subspecialty textbook comprehensively addressing clinical and etiopathogenetic issues relating to the cutaneous manifestations of dermatomyositis. Includes a number of color photographs of representative dermatomyositis skin changes.
   Google Scholar
• WAGNER B, KAGAN-HALLET KS, RUSSELL IJ iet al.: i Concomitant presentation of adermatopathic dermatomyositis, statin myopathy, fibromyalgia syndrome, piriformis muscle myofascial pain syndrome, and diabetic neuropathy. iMusculoskelet. Pain i (2003) 11(2):25–30.
   Google Scholar
• DALAKAS MC, HOHLFELD R: Diagnostic criteria for polymyositis and dermatomyositis. iLancet i (2003) 362(9397):1763.
   PubMed Web of Science ®Google Scholar
• EUWER RL, SONTHEIMER RD: Amyopathic dermatomyositis (dermatomyositis sine myositis) Presentation of six new cases and review of the literature.f iAm. Acad. Dermatol i (1991) 24:959–966.
   PubMed Web of Science ®Google Scholar
• DAWKINS MA, JORRIZO JL, WALKER FO iet al.: i Dermatomyositis: a dermatology-based case series. iAm. Acad. Dermatol i (1998) 38(3):397–404.
   Google Scholar
• SONTHEIMER RD: Cutaneous features of classical dermaytomyositis and amyopathic dermatomyositis. iCarr: Opin. Rheumatol i (1999) 11:475–482.
   PubMedGoogle Scholar
• SONTHEIMER RD: Would a new name hasten the acceptance of clinically-amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?' iAm. Acad. Dermatol i (2002) 46:626–636.
   PubMed Web of Science ®Google Scholar
• •A dermatologist's perspective on the nomenclature and classification of dermatomyositis skin disease and the idiopathic inflammatory myopathies. Issues relating to clinically-amyopathic dermatomyositis are especially emphasised.
   Google Scholar
• SONTHEIMER RD: Dermatomyositis. an overview of recent progress with emphasis on dermatological aspects. iDermatol Clin. i (2002) 20:387–408.
   Google Scholar
• COHEN JB: Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. iInt. Dermatol i (2002) 41:182–184.
   PubMed Web of Science ®Google Scholar
• •Among first reports to confirm that inflammatory dermatomyositis skin disease can respond to Dapsone and that some patients can experience the hallmark cutaneous manifestations of dermatomyositis for 20 years without developing clinically evident muscle weakness.
   Google Scholar
• EL-AZHARY R, PAKZAD SY: Amyopathic dermatomyositis: retrospective review of
   Google Scholar
• cases. iAm. Acad. Dermatol i (2002) 46:560–565.
   Google Scholar
• •A retrospective follow-up analysis of 37 amyopathic dermatomyositis patients seen at the Mayo Clinic. While not using the specific terminology, several patients in this report that would fulfill the modern definition of hypomyopathic dermatomyositis were followed up after long periods of time using a postal questionnaire. None were found to have developed clinically evident weakness.
   Google Scholar
• SONTHEIMER RD, MIYAGAWA S: Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. iAm. Acad. Dermatol i (2003) 48(5):797–798.
   PubMed Web of Science ®Google Scholar
• •A letter to the editor summarising the English and Japanese language literature to emphasise the fact that potentially fatal interstitial lung disease can develop in clinically-amyopathic dermatomyositis patients.
   Google Scholar
• HIGH WA, COHEN JB, MURPHY BA, COSTNER MI: Fatal interstitial pulmonary fibrosis in anti-Jo-l-negative amyopathic dermatomyositis. iJ. Am. Acad. Dermatol i (2003) 49:295–298.
   PubMed Web of Science ®Google Scholar
• TARGOFF IN, TRIEU EP, SONTHEIMER RD: Autoantibodies to 155 kD and Se autoantigens in patients with clinically-amyopathic dermatomyositis. iArthritis Rheum. i (2000) 43\(Suppl. 9):5194.
   Google Scholar
• •A retrospective analysis of 13 Italian amyopathic dermatomyositis patients identified from a cohort of 157 dermatomyositis patient seen over a 10-year period by the Italian Group of Irnmunodermatology of the Italian Society of Dermatology and Venereology. Of these 13 amyopathic dermatomyositis patients, none experienced an associated internal malignancy.
   Google Scholar
• SATO S, SUVVA A, KUWANA M iet al: i Clinical and immunological associations of autoantibodies to the 140 kDa polypeptide (the US autoantigen) in patients with clinically amyopathic dermatomyositis. iArthritis Rheum. i (2003) 48:S102.
   Google Scholar
• LOVE LA, LEFF RL, FRASER DD iet al: i A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. iMedicine (Baltimore) i (1991) 70:360–374.
   PubMed Web of Science ®Google Scholar
• WATANABE C, OKUBO Y, OHI T iet al: i A case of dermatomyositis associated with mechanic's hand. iDermatol i (2000) 27(11):711–716.
   PubMedGoogle Scholar
• CAPRONI M, CARDINALI C, PARODI A iet al: i Amyopathic dermatomyositis - a review by the Italian group of immunodermatology. iArch. Dermatol i (2002) 138(1):23–27.
   PubMedGoogle Scholar
• TRAUTMANN C, ABDEL-NASER MB, SOEHNCHEN R iet al.: i Pre-myopathic versus amyopathic dermatomyositis. 2 personal cases and review of the literature. iHautarzt i (1995) 46(1):47–52.
   Google Scholar
• TING WW, SONTHEIMER RD: Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. iLupus i (2001) 10:171–184.
   Google Scholar
• •A comprehensive review of local therapy for cutaneous and systemic lupus erythematosus, much of which has relevance to the management of dermatomyositis skin disease.
   Google Scholar
• SONTHEIMER RD, GEERS DL: Skin disease in dermatomyositis-What patients and their families often want to know. iDerm. Online 1 i (2002) 20:387–408.
   Google Scholar
• •A 'frequently asked question' format of information concerning the cutaneous manifestations of dermatomyositis written for patients and their family members. Available in a free, public access online journal.28. YOSHIMASU T, OHTANI T, SAKAMOTO T iet al: i Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. iEar: j Dermatol i (2002) 12(1):50–52.
   Google Scholar
• WALKER SL, KIRBY B, CHALMERS RJG: The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. iBr J. Dermatol i (2002) 147(2):405–406.
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH, OCHSENDORF F, PAESLACK I iet al.: i Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. iEur. Dermatol i (2002) 12(6):577–580.
   Google Scholar
• PELLE MT, CALLEN JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. iArch. Dermatol i (2002) 138 (9) :1231–1233.
   PubMedGoogle Scholar
• MARMOR ME CARR RE, EASTERBROOK M iet al.: i Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. iOphthalmology (2002) i 109(7):1377–1382.
   Google Scholar
• MARMOR MF: New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. iArthritis Rheum. i (2003) 48(6):1764.
   PubMedGoogle Scholar
• KONOHANA A, KAWASHIMA J: Successful treatment of dermatomyositis with dapsone. iClin. Exp. Dermatol i (1994) 19(4):367.
   PubMed Web of Science ®Google Scholar
• SADAYAMA T, MIYAGAWA S, SHIRAI T: Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. i.1. Dermatol (1999) i 26(7):457–459.
   Google Scholar
• NUNEZ M, BOIXEDA P, MIRALLES ES iet al.: i Pulsed dye laser treatment in lupus erythematosus telangiectoides [letter]. iBr: J. Dermatol i (1995) 133(6):1010–1011.
   Google Scholar
• RAULIN C, SCHMIDT C, HELLWIG S: Cutaneous lupus erythematosus-treatment with pulsed dye laser. iELI Dermatol i (1999) 141(6):1046–1050.
   Web of Science ®Google Scholar
• NASSIM JR, CONNOLLY CK: Treatment of calcinosis universalis with aluminium hydroxide. iArch. Dis. Child i (1970) 45:118–121.
   PubMed Web of Science ®Google Scholar
• WANG WJ, LO WL, WONG CK: Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. iArch. Dermatol i (1988) 124:1721–1722.
   PubMedGoogle Scholar
• NAKAGAWA T, TAKAIWA T: Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. iDermatol i (1993) 20:558–560.
   PubMedGoogle Scholar
• DENT CE, STAMP TCB: Treatment of calcinosis circumscripta with probenecid. iBr. Med. J. i (1972) 1:216.
   PubMedGoogle Scholar
• SKUTERUD E, SYDNES OA, HAAVIK TK: Calcinosis in dermatomyositis treated with probenecid. iScand. Rheumatol i (1981) 10:92–94.
   PubMed Web of Science ®Google Scholar
• ROWELL NR, GOODFIELD MJD: The 'Connective Tissue Diseases'. In: iTextbook of Dermatology i Champion RH, Burton JL, Ebling FJG (Eds), Blackwell Scientific Publications, London, UK (1992):2163–2294.
   Google Scholar
• BERGER RG, FEATHERSTON GL, RAASON RH: Treatment of calcinosis universalis with low dose warfarin. iAm. J. Med. i (1987) 83:72–76.
   Google Scholar
• MARTINEZ-CORDERO E, LOPEZ-ZEPEDA J, CHOZA-ROMERO F: Calcinosis in childhood dermatomyositis [letter]. iGin. Exp. Rheumatol i (1990) 8:198–200.
   PubMed Web of Science ®Google Scholar
• OLIVERI MB, PALERMO R, MAUTALEN C iet al.: i Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. iRheumatol i (1996) 23(12):2152–2155.
   Google Scholar
• LASSOUED K, SAIAG P, ANGLADE MC iet al.: i Failure of warfarin in treatment of calcinosis universalis. iAm. J. Med. i (1988) 84:795–796.
   Google Scholar
• HERD JK, VAUGHAN JH: Calcinosis universalis complicating dermatomyositis. iArthritis Rheum. i (1964) 7:259–271.
   PubMed Web of Science ®Google Scholar
• TABORN J, BOLE GG, THOMPSON GR: Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. iAnn. Intern. Med. i (1978) 89:648–649.
   PubMed Web of Science ®Google Scholar
• MUKAMEL M, HOREV G, MIMOUNI M: New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. iPediatr. i (2001) 138(5):763–766.
   Google Scholar
• SHEARIN JC, PICKRELL K: Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis. iAnn. Plast. Surg. i (1980) 5:381–385.
   PubMedGoogle Scholar
• RAHMAN P, GLADMAN DD, UROWITZ MB: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. iJ. Rheumatol i (1998) 25:1716–1719.
   Web of Science ®Google Scholar
• JEWELL ML, MCCAULIFFE DP: Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. iAm. Acad. Dermatol i (2000) 42(6):983–987.
   PubMed Web of Science ®Google Scholar
• ISHII N, ONO H, KAWAGUCHI T iet al.: i Dermatomyositis and pregnancy. Case report and review of the literature. [Review]. iDermatologica. i (1991) 183:146–149.
   Google Scholar
• OHNOT, i IMAI A, TAMAYA T: Successful outcomes of pregnancy complicated with dermatomyositis case reports. iGynecol Obstet. Invest. i (1992) 33:187–189.
   Google Scholar
• KRAIN L: Dermatomyositis in six patients without initial muscle involvement. iArch. Dermatol i (1975) 111:241–245.
   PubMedGoogle Scholar
• •Among the earliest reports in the modern literature describing the clinical and lab features of a small cohort of patients that would fulfill the modem definition of clinically-amyopathic dermatomyositis but went on to develop clinically-evident muscle weakness after several years.
   Google Scholar
• EUWER R, SONTHEIMER RD: Amyopathic dermatomyositis-a review. iJ. Invest. Dermatol (1993) i 100:124S–127S.
   Google Scholar
• SONTHEIMER RD: A portable digital microphotography unit for rapid bedside documentation of periungual nailfold capillary changes seen in autoimmune connective tissue diseases. iRheumatol i (2004) 31 (3) :539–544.
   Web of Science ®Google Scholar
• CROWSON AN, MAGRO CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. iHum. Pathol i (1996) 27(1):15–19.
   Web of Science ®Google Scholar
• MASCARO JM Jr, HAUSMANN G, HERRERO C iet al.: i Membrane attack complex deposits in cutaneous lesions of dermatomyositis. iArch. Dermatol i (1995) 131(12):1386–1392.
   Google Scholar
• THUNE P: The coexistence of amyopathic dermatomyositis and fibromyalgia. iActa. Berm. Venereol i (2000) 80(6):453–454.
   PubMed Web of Science ®Google Scholar
• LANGLO L: The efficacy of local application of chloroquine and mepacrine in preventing the effects of ultraviolet rays on human skin. iActa. DermatolVenerol i (1957) 27:85.
   Google Scholar
• KUTINTSCHEV M, CHLEBAROV S: Treatment of lupus erythematosus by iontophoresis with plaquenil. iZ. Haut. Geschlechtskr. i (1967) 42(22):676–678.
   PubMedGoogle Scholar
• EVERETT MA, COFFEY CM: Intradermal administration of chloroquine. iArch. Dermatol i (1961) 83:977–979.
   PubMedGoogle Scholar
• WERTH VP, CALLEN JP, ANG G iet al.: i Associations of tumor necrosis factor alpha and HLA polymorphisms with adult1098 dermatomyositis: Implications for a unique pathogenesis. iJ. Invest. Dermatol. i (2002) 119(3):617–620.
   Google Scholar
• HENGSTMAN GJ, VAN DEN HOOGEN FH, BARRERA P iet al.: i Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. iEur: Nemo]. i (2003) 50(1):10–15.
   Google Scholar
• •Among the first formal reports to suggest that dermatomyositis and polymyositis patients might be responsive to TNF-a blocking/inhibiting biological drugs.
   Google Scholar
• SAADEH CK: One member's story: Enbreluse restored his strength. iThe Outlook for the i Inflammatory Myopathies (Myosins iAssociation of America) i June 11(2000). Myositis Association of America.
   Google Scholar
• HENGSTMAN G, VAN DEN HOOGEN F, VAN ENGELEN B iet al.: i Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. iThe i Outlook for the Inflammatory Myopathies March 17 (2001). Myositis Association of America.
   Google Scholar
• NZEUSSEU A., DUREZ P, HOUSSIAU F iet al.: i Successful use of infliximab in a case of refractory juvenile dermatomyositis. iArthritic Rheum. i (2001) 44 (9) :S90–S–90.
   Google Scholar
• BLEUMINK GS, TER BORG EJ, RAMSELAAR CG iet al.: i Etanercept-induced subacute cutaneous lupus erythematosus. iRheumatology i (2001) 40(11):1317–1319.
   Google Scholar
• ALT Y, SHAH S: Infliximab-induced systemic lupus erythematosus. iAnn. Int. Med. i (2002) 137(7):625–626.
   Web of Science ®Google Scholar
• KAPLAN M: Eculizumab (Alexion). iCLIFF. Opin. Investig. Drugs i (2002)3(7):1017–1023.
   PubMedGoogle Scholar
• •Among the first formal reports to suggest that dermatomyositis patients might be responsive to biological drugs that blocldinhibit the fifth component of complement.
   Google Scholar
• SHAW T, QUAN J, TOTORITIS MC iet al.: i B cell therapy for rheumatoid arthritis: the ritwdmab (anti-CD20) experience. iAnn Rheum. Dis. i (2003) 62 (Suppl. 2):55–59.
   Google Scholar
• PERROTTA S, LOCATELLI F, LA MANNA A iet al.: i Anti-CD20 monoclonal antibody (Ritwdmab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. iBr. .1. Haematol. i (2002) 116(2):465–467.
   Google Scholar
• KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with ritwdmab in the treatment of autoimmune diseases. iImmunobiology (2002) i 206 (5) : 519–527.
   Google Scholar
• GOEBELER M, HERZOG S, BROCKER EB iet al.: i Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. iBr. J. Dermatol. i (2003) 149(4):899–901.
   Google Scholar
• SALOPEK TG, LOGSETTY S, TREDGET EE: Anti-CD20 chimeric monoclonal antibody (ritwdmab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. iAm. Acad. Dermatol. i (2002) 47(5):785–788.
   PubMed Web of Science ®Google Scholar
• GERDESMEYER L, WAGENPFEIL S, HAAKE M iet al.: i Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a randomized controlled trial. iJAMA i (2003) 290(19):2573–2580.
   Google Scholar
• COSENTINO R, DE STEFANO R, SELVI E iet al.: i Extracorporeal shock wave therapy for chronic calcific tendinitis of the shoulder: single blind study. iAnn. Rheum. Dis. i (2003) 62(3):248–250. Websites
   Google Scholar
• http://tray.dermatology.uiowa.edu/DM/DM/ sld001.htm Skin problems experienced by dermatomyositis patients. Myositis Association of America Conference, Atlanta, GA, USA. September, 2002. Slides by RD Sontheimer.
   Google Scholar
• http://www.myositis.org/ The Myositis Association.
   Google Scholar
• http://www.clinicaltrials.gov/ct/show/NCTO 0001680?order = 1 A Pilot trial of topical thalidomide for the management of chronic discoid lupus erythematosus.
   Google Scholar
• http://www.clinicaltrials.gov/ct/show/NCTO 0033891?order = 1 Infliximab (Remicade®) to treat dermatomyositis and polymyositis. Affiliation Richard D Sontheimer MD Department of Dermatology, University of Iowa Carver College of Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, BT2045-1, Iowa City, Iowa 52242, USA Tel: +1(319) 356–3609; Fax: +1(319) 356–8317; E-mail: [email protected]
   Google Scholar